New progress Quanxin Biologics QX002N injection for new indications obtained implied permission from clinical trials

Recent popular reports from Yimaike ★How much do you know about AAV gene therapy for hemophiliaYikemai classroom★ "Spot" G-NK cells are here! Pre-clinical data show stronger tumor lethalityMedMeng broke the news October 20, 2021/MedClub News/---October 19, QX002N injection of QX002N was acquired as a new indication for lupus nephritis Implied permission for clinical trials
.

QX002N injection QX002N injection is a recombinant humanized anti-IL-17A monoclonal antibody injection.
It is the first class I innovative drug independently developed by Quanxin Biology.
The proposed development indications include ankylosing spondylitis, lupus nephritis and silver Squamous arthritis and so on
.

The project is currently conducting Phase 2 clinical trials for adults with active ankylosing spondylitis
.

Lupus nephritis (LN) refers to a disease in which systemic lupus erythematosus (SLE) is associated with different pathological types of immune damage in both kidneys and accompanied by clinical manifestations of obvious kidney damage
.

Systemic lupus erythematosus is a chronic systemic autoimmune disease.
The main clinical features are multi-system and multi-organ involvement, repeated relapse and remission, and the presence of a large number of autoantibodies in the body.
If not treated in time, it will cause organ involvement.
The irreversible damage eventually led to the death of the patient, with a population incidence of 30.
13 to 70.
41 per 100,000 people
.

The clinical manifestations of SLE can involve the skin, serosal membranes, joints, kidneys and central nervous system, among which the kidney is one of the organs most frequently involved in SLE.
40% to 60% of SLE patients have lupus nephritis at the beginning
.

The clinical manifestations of LN vary in severity.
In addition to the systemic manifestations of SLE, it also has typical renal manifestations.
The mild cases have only a small amount of proteinuria and/or hematuria, and the severe cases have nephrotic syndrome or rapidly progressive glomerulonephritis
.

In addition, the pathological changes of the kidneys are more diverse.
Mild lesions can be mild glomerular lesions, and severe ones can manifest as diffuse proliferative nephritis or even crescentic nephritis
.

Studies have shown that IL-17 and IL-17-producing cells can infiltrate the kidneys and act synergistically with other cytokines to cause local inflammation in the kidneys
.

IL-17A inhibitors can specifically target and bind IL-17A derived from innate immune and acquired immune cells, block its binding to IL-17RA/C on the target cell membrane, thereby rapidly inhibiting downstream inflammatory cytokines and chemokines The network, in turn, may have a therapeutic effect on a variety of immune diseases mediated by IL-17A
.

The exploration of QX002N injection in the field of lupus nephritis is expected to bring more medication options and better treatment options to patients
.